GMP Quality Concerns Prompt Indian Drug Regulator To Plan Overseas Site Inspections, Mainly In China
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - As part of plans to beef up checks of imported drugs and intermediates, the Drug Controller General of India is proposing to send its own agents to large manufacturing plants across the world to inspect and establish compliance with good manufacturing practice standards
You may also be interested in...
India's DCGI Halts Avandia's TIDE Trial Aimed At Proving CV Safety; Steps Up Review of "Controversial Drugs" Sold In India
MUMBAI - GlaxoSmithKline may be temporarily relieved after U.S. FDA's joint advisory committee recommended that GSK's controversial anti-diabetes drug Avandia (rosiglitazone) remain on the market; but dealing with the product seems to be getting tougher for the company in countries like India
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).